News
The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...
US FDA accepts for priority review Bristol Myers Squibb’s sBLA for Breyanzi to treat adult patients with relapsed or refractory MZL: Princeton, New Jersey Wednesday, August 6, 2 ...
Zacks.com on MSN3h
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
BMY trims earnings outlook despite revenue beat and upbeat drug sales, sending shares to a 52-week low before a rebound. We ...
Based on positive Phase II TRANSCEND FL data showing a 95.5% overall response rate, the FDA has accepted Bristol Myers Squibb’s sBLA for Breyanzi in relapsed or refractory MZL with a PDUFA date set ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback